argenx SE 2023 SR
The report highlights argenx's mission to transform autoimmune disease treatment, focusing on the global expansion of its first-in-class treatment, VYVGART. In 2023, the company doubled the number of patients benefiting from VYVGART and advanced its clinical pipeline with 24 active trials. Key ESG achievements include reaching over 6,000 patients globally, maintaining a zero workplace accident rate for the fifth consecutive year, and conducting its first comprehensive greenhouse gas emissions calculation. The company also emphasized its Immunology Innovation Program (IIP) and commitment to diversity, equity, and inclusion, with women making up 33.3% of the Board of Directors.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2023
Type: SR
Pages: 66
Back to company
argenx SE
ESG Report
The report highlights argenx's mission to transform autoimmune disease treatment, focusing on the global expansion of its first-in-class treatment, VYVGART. In 2023, the company doubled the number of patients benefiting from VYVGART and advanced its clinical pipeline with 24 active trials. Key ESG achievements include reaching over 6,000 patients globally, maintaining a zero workplace accident rate for the fifth consecutive year, and conducting its first comprehensive greenhouse gas emissions calculation. The company also emphasized its Immunology Innovation Program (IIP) and commitment to diversity, equity, and inclusion, with women making up 33.3% of the Board of Directors.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Workplace Fatalities
Employees